These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29185966)

  • 1. The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis.
    Bornstein G; Lidar M; Langevitz P; Fardman A; Ben-Zvi I; Grossman C
    Clin Exp Rheumatol; 2018; 36(2):228-232. PubMed ID: 29185966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment.
    Patil A; Upadhyaya S; Dawar R; Dadhaniya N; Sood I; Gupta SJ; Handa R
    Int J Rheum Dis; 2019 Sep; 22(9):1638-1643. PubMed ID: 31211501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
    Bouden S; Laadhar L; Soua J; Ben Messaoud M; Rouached L; Ayadi I; Saidane O; Ben Tekaya A; Mahmoud I; Rekik S; Srairi HS; Tekaya R; Bellakhal S; Fekih M; Abdelmoula L; Kallel M
    Curr Rheumatol Rev; 2024; 20(4):435-443. PubMed ID: 38314598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis.
    Hwang J; Kim HM; Jeong H; Lee J; Ahn JK; Koh EM; Kang ES; Cha HS
    Rev Bras Reumatol Engl Ed; 2017; 57(4):311-319. PubMed ID: 28743358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.
    Padilla-Martínez EM; Romero-Sanchez C; Bello-Gualtero JM; Mesa-Betancourt AM; Bautista-Molano W; Valle-O R
    Curr Rheumatol Rev; 2019; 15(4):329-335. PubMed ID: 31284866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.
    Arstikyte I; Kapleryte G; Butrimiene I; Venalis A
    Biomed Res Int; 2015; 2015():604872. PubMed ID: 26064930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.
    Senabre Gallego JM; Rosas J; Marco-Mingot M; García-Gómez JA; Santos-Soler G; Salas-Heredia E; Pons-Bas A; Barber-Vallés X; Bernal-Vidal JA; Cano-Pérez C; García-Carrasco M; Flores-Pardo E;
    Rheumatol Int; 2019 May; 39(5):841-849. PubMed ID: 30899987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
    Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.
    Weiß A; Song IH; Haibel H; Listing J; Sieper J
    Arthritis Res Ther; 2014 Jan; 16(1):R35. PubMed ID: 24476416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
    Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
    Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
    Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.
    Hiltunen J; Parmanne P; Sokka T; Lamberg T; Isomäki P; Kaipiainen-Seppänen O; Peltomaa R; Uutela T; Pirilä L; Taimen K; Kauppi MJ; Yli-Kerttula T; Tuompo R; Relas H; Kortelainen S; Paalanen K; Asikainen J; Ekman P; Santisteban A; Vidqvist KL; Tadesse K; Romu M; Borodina J; Elfving P; Valleala H; Leirisalo-Repo M; Rantalaiho V; Kautiainen H; Jokiranta TS; Eklund KK;
    Rheumatol Int; 2022 Jun; 42(6):1015-1025. PubMed ID: 34357455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.
    Plasencia C; Pascual-Salcedo D; García-Carazo S; Lojo L; Nuño L; Villalba A; Peiteado D; Arribas F; Díez J; López-Casla MT; Martín-Mola E; Balsa A
    Arthritis Res Ther; 2013 Jul; 15(4):R79. PubMed ID: 23890223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.
    Vincent FB; Pavy S; Krzysiek R; Lequerré T; Sellam J; Taoufik Y; Mariette X; Miceli-Richard C
    Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773
    [No Abstract]   [Full Text] [Related]  

  • 19. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
    Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
    PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.
    Lian F; Zhou J; Wei C; Wang Y; Xu H; Liang L; Yang X
    Clin Rheumatol; 2015 Nov; 34(11):1913-20. PubMed ID: 26070537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.